Profile data is unavailable for this security.
About the company
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. It is focused on translating insights from genetic epilepsies into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, is an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. Its product candidates include ulixacaltamide, PRAX-562, PRAX-628 and elsunersen.
- Revenue in USD (TTM)2.45m
- Net income in USD-123.28m
- Incorporated2015
- Employees82.00
- LocationPraxis Precision Medicines Inc99 High Street, 30th FloorBOSTON 02110United StatesUSA
- Phone+1 (617) 300-8460
- Fax+1 (302) 655-5049
- Websitehttps://praxismedicines.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nuvation Bio Inc | 0.00 | -75.80m | 821.49m | 51.00 | -- | 1.21 | -- | -- | -0.3463 | -0.3463 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -11.72 | -16.27 | -11.97 | -16.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.25 | -- | -- | -- |
Evolus Inc | 219.70m | -60.00m | 822.08m | 279.00 | -- | 44.33 | -- | 3.74 | -1.05 | -1.05 | 3.82 | 0.2962 | 1.14 | 3.86 | 7.62 | 804,750.90 | -31.06 | -40.92 | -40.14 | -59.74 | 69.28 | 65.43 | -27.31 | -80.46 | 2.96 | -2.90 | 0.8674 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
Nurix Therapeutics Inc | 80.89m | -144.73m | 827.29m | 284.00 | -- | 4.06 | -- | 10.23 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
Tango Therapeutics Inc | 37.23m | -111.65m | 829.33m | 140.00 | -- | 3.14 | -- | 22.27 | -1.11 | -1.11 | 0.3742 | 2.48 | 0.0919 | -- | -- | 265,942.80 | -27.57 | -- | -31.29 | -- | -- | -- | -299.88 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
Pliant Therapeutics Inc | 248.00k | -170.74m | 833.00m | 158.00 | -- | 1.90 | -- | 3,358.88 | -2.86 | -2.86 | 0.0042 | 7.25 | 0.0004 | -- | 0.0701 | 1,569.62 | -30.50 | -33.24 | -32.04 | -35.39 | -- | -- | -68,847.98 | -360.29 | -- | -- | 0.0642 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
Relay Therapeutics Inc | 35.33m | -329.12m | 837.60m | 309.00 | -- | 1.12 | -- | 23.71 | -2.64 | -2.64 | 0.2841 | 5.64 | 0.0376 | -- | -- | 109,371.50 | -35.03 | -28.55 | -37.16 | -29.54 | -- | -- | -931.64 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
ARS Pharmaceuticals Inc | 30.00k | -54.37m | 852.67m | 24.00 | -- | 3.68 | -- | 28,422.36 | -0.5719 | -0.5719 | 0.0003 | 2.39 | 0.0001 | -- | -- | 1,250.00 | -21.13 | -20.37 | -21.45 | -21.32 | -- | -- | -181,216.70 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
Longboard Pharmaceuticals Inc | 0.00 | -57.95m | 854.97m | 50.00 | -- | 2.73 | -- | -- | -2.25 | -2.25 | 0.00 | 8.07 | 0.00 | -- | -- | 0.00 | -28.45 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
ALX Oncology Holdings Inc | 0.00 | -160.81m | 855.96m | 72.00 | -- | 4.46 | -- | -- | -3.74 | -3.74 | 0.00 | 3.80 | 0.00 | -- | -- | 0.00 | -58.58 | -34.34 | -66.35 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0592 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
Praxis Precision Medicines Inc | 2.45m | -123.28m | 856.93m | 82.00 | -- | 6.32 | -- | 350.20 | -23.64 | -23.64 | 0.3719 | 7.92 | 0.0241 | -- | -- | 29,841.46 | -121.41 | -74.04 | -161.17 | -85.12 | -- | -- | -5,037.88 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
89bio Inc | 0.00 | -142.19m | 867.50m | 70.00 | -- | 1.58 | -- | -- | -2.01 | -2.01 | 0.00 | 5.75 | 0.00 | -- | -- | 0.00 | -35.86 | -45.50 | -38.49 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0442 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
OPKO Health Inc | 799.60m | -252.43m | 878.21m | 3.93k | -- | 0.701 | -- | 1.10 | -0.3427 | -0.3427 | 1.08 | 1.80 | 0.3859 | 7.53 | 6.87 | 203,461.30 | -12.18 | -7.14 | -13.58 | -8.14 | 32.63 | 34.42 | -31.56 | -13.83 | 1.58 | -4.96 | 0.2217 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
USANA Health Sciences, Inc. | 900.45m | 61.94m | 882.42m | 1.80k | 14.46 | 1.76 | 11.84 | 0.98 | 3.20 | 3.20 | 46.56 | 26.25 | 1.46 | 2.73 | -- | 500,250.00 | 10.03 | 16.23 | 12.49 | 21.75 | 80.98 | 81.42 | 6.88 | 8.96 | 3.20 | -- | 0.0026 | 0.00 | -7.77 | -4.98 | -8.02 | -12.76 | 4.86 | -- |
Viridian Therapeutics Inc | 288.00k | -218.13m | 887.77m | 96.00 | -- | 2.32 | -- | 3,082.54 | -4.50 | -4.50 | 0.0058 | 9.13 | 0.0006 | -- | 2.50 | 3,063.83 | -42.89 | -55.59 | -45.38 | -60.32 | -- | -- | -75,737.84 | -5,678.12 | -- | -- | 0.0337 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
Zentalis Pharmaceuticals Inc | 40.56m | -218.90m | 889.09m | 168.00 | -- | -- | -- | 21.92 | -3.36 | -3.36 | 0.5934 | -- | -- | -- | -- | 241,428.60 | -- | -47.40 | -- | -54.18 | -- | -- | -506.16 | -- | -- | -- | -- | -- | -- | -- | -23.39 | -- | 20.76 | -- |
Holder | Shares | % Held |
---|---|---|
Point72 Asset Management LPas of 31 Dec 2023 | 758.19k | 5.73% |
Adage Capital Management LPas of 31 Dec 2023 | 738.67k | 5.58% |
Verition Fund Management LLCas of 31 Dec 2023 | 703.00k | 5.31% |
PFM Health Sciences LPas of 31 Dec 2023 | 656.55k | 4.96% |
Cormorant Asset Management LPas of 31 Dec 2023 | 633.35k | 4.78% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 366.24k | 2.77% |
Kingdon Capital Management LLCas of 31 Dec 2023 | 346.67k | 2.62% |
Velan Capital Investment Management LPas of 31 Dec 2023 | 345.67k | 2.61% |
Sphera Funds Management Ltd.as of 31 Dec 2023 | 328.99k | 2.49% |
Acuta Capital Partners LLCas of 31 Dec 2023 | 299.64k | 2.26% |